ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1490

Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials

Camila Pinto1, Joana Barroso2 and Thomas Schnitzer3, 1Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: ACR Convergence 2020

Keywords: clinical trial, Osteoarthritis, Outcome measures, pain, Response Criteria

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Osteoarthritis II: Clinical Aspects (1487–1491)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain reports and do not take in consideration the dynamic effects of daily pain on the response to treatment. In this study we examined the between- and within-subject variability in pain ratings and their value as a predictor of treatment response.

Methods: Three hundred and eighty-nine osteoarthritis patients (OA) enrolled as part of a clinical trial (NCT00809783) were randomized in two groups: Naproxen 500 mg twice a day (NAP; n=113) and Placebo (PBO; n=276). All participants were to complete daily pain intensity diaries using a numeric rating scale (NRS; 0 to 10 points) for a period of 127 days (15 days before + 112 days during treatment). A logistic regression analysis of responders (30% pain improvement) and a linear longitudinal model were performed to determine whether the pre-treatment pain variation (standard deviation of pain, SD) was associated with treatment response and decreases in pain intensity.

Results: Longitudinal pain decrease was observed over time (NRS SD) with both treatments (p< 0.001); pain variability (PV) within subjects was stable over time (Pearson’s R, pre/post treatment SD: PBO r= 0.37, p< 0.00; NAP=0.21 p=0.03). Pre-treatment pain variability significantly predicted response after 4, 8, 12 and 16 weeks (Table 1, p< 0.05). Next, we investigated the treatment effects subclassifying treatment groups based on their pain variability. The high variability NAP subgroup presented significantly larger improvement in pain than the low variability subgroup (p< 0.001), and a similar trend was observed for the placebo group (p=0.09) (Figure 1).

Conclusion: Pain variability in patients with OA seems to be stable over time and independent of mean pain reduction. Pre-treatment higher pain variability associates both with categorical response to treatment (30% recovery), and linear pain reduction, thus constituting a marker of treatment response and a possible important effect to control for in OA clinical trials.

Table 1. Results of logistic regression analysis of clinical pain responders*

Figure 1: Longitudinal daily pain decreases over time. a. There is significant difference in pain decrease over time between high and low Naproxen groups (p < 0.001). b. There is a significant decrease of pain over time, but not significant difference between high and low Placebo groups (p=0.09).


Disclosure: C. Pinto, None; J. Barroso, None; T. Schnitzer, Pfizer, 1, 2, Lilly, 1, 2, Regeneron, 1, AstraZeneca, 1.

To cite this abstract in AMA style:

Pinto C, Barroso J, Schnitzer T. Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/pain-rating-variability-and-response-to-treatment-in-osteoarthritis-clinical-trials/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pain-rating-variability-and-response-to-treatment-in-osteoarthritis-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology